{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:04:47Z","timestamp":1787504687759,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004332","name":"Seoul National University Hospital","doi-asserted-by":"publisher","award":["03-2021-0210"],"award-info":[{"award-number":["03-2021-0210"]}],"id":[{"id":"10.13039\/501100004332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2021R1A2C2007430"],"award-info":[{"award-number":["2021R1A2C2007430"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Trastuzumab resistance in HER2-positive cancers remains a significant clinical challenge with limited therapeutic options. Although the tumor-promoting role of the Yes-associated protein (YAP) pathway is well established, its role in trastuzumab resistance remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We established four trastuzumab-resistant (HR) cell lines (NCI-N87HR, SNU216HR, SNU2670HR, and SNU2773HR) from HER2-positive gastric cancer and biliary tract cancer cell lines. YAP pathway activation was assessed using Phospho-RTK arrays, bulk RNA-Seq, and immunofluorescence. Antitumor effects of YAP targeting were evaluated with MTT assays, cell-cycle analysis, migration assays, RT-qPCR, ELISA, and xenograft models of SNU-2773 and SNU-2773HR cells. Immune modulation by YAP was studied through co-culture experiments with human PBMCs and cancer cells, followed by flow cytometry analysis of immune markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Upregulation and activation of the YAP\/TAZ pathway were observed in HR cells, indicated by elevated ROR2 levels and nuclear translocation of YAP. This activation, driven by YAP\/TEAD-dependent Wnt5a expression, suggests a positive-feedback mechanism that amplifies YAP activity. Elevated YAP and TEAD levels were observed in patient tumor tissues during disease progression following HER2-targeted therapies. Targeting YAP disrupted its oncogenic effects and restored sensitivity to trastuzumab, increased activation of CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells in PBMCs, likely via PD-L1 downregulation and enhanced immunogenic cell death. Verteporfin, a YAP-TEAD inhibitor, effectively reduced tumor growth and increased apoptosis in mouse models bearing HR tumors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Targeting the ROR2-YAP\/TEAD axis presents a promising therapeutic approach to overcome trastuzumab resistance in HER2-positive cancers, offering a potential strategy for enhancing treatment efficacy and improving clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10120-025-01630-w","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T14:01:19Z","timestamp":1750428079000},"page":"799-813","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["YAP as a therapeutic target to reverse trastuzumab resistance"],"prefix":"10.1007","volume":"28","author":[{"given":"Ah-Rong","family":"Nam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Seok","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Hee","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoojin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sea Young","family":"Choo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su In","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeesun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-9901","authenticated-orcid":false,"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"1630_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"DY Oh","year":"2020","unstructured":"Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17:33\u201348. https:\/\/doi.org\/10.1038\/s41571-019-0268-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"1630_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet"},{"key":"1630_CR3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/Nejm200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med. 2001;344:783\u201392. https:\/\/doi.org\/10.1056\/Nejm200103153441101.","journal-title":"New Engl J Med"},{"key":"1630_CR4","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:1659\u201372. https:\/\/doi.org\/10.1056\/NEJMoa052306.","journal-title":"N Engl J Med"},{"key":"1630_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40364-024-00565-1","volume":"12","author":"K Zhu","year":"2024","unstructured":"Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H. HER2-targeted therapies in cancer: a systematic review. Biomark Res. 2024;12:16. https:\/\/doi.org\/10.1186\/s40364-024-00565-1.","journal-title":"Biomark Res"},{"key":"1630_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00924-9","author":"J Yoon","year":"2024","unstructured":"Yoon J, Oh DY. HER2-targeted therapies beyond breast cancer - an update. Nat Rev Clin Oncol. 2024. https:\/\/doi.org\/10.1038\/s41571-024-00924-9.","journal-title":"Nat Rev Clin Oncol"},{"key":"1630_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102500","volume":"113","author":"C von Arx","year":"2023","unstructured":"von Arx C, De Placido P, Caltavituro A, Di Rienzo R, Buonaiuto R, De Laurentiis M, et al. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. Cancer Treat Rev. 2023;113: 102500. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102500.","journal-title":"Cancer Treat Rev"},{"key":"1630_CR8","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1209124.","journal-title":"N Engl J Med"},{"key":"1630_CR9","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cortes","year":"2022","unstructured":"Cortes J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2115022.","journal-title":"N Engl J Med"},{"key":"1630_CR10","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","volume":"382","author":"K Shitara","year":"2020","unstructured":"Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu MH, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382:2419\u201330. https:\/\/doi.org\/10.1056\/NEJMoa2004413.","journal-title":"N Engl J Med"},{"key":"1630_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazieres J, et al. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. N Engl J Med. 2022;386:241\u201351. https:\/\/doi.org\/10.1056\/NEJMoa2112431.","journal-title":"N Engl J Med"},{"key":"1630_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"key":"1630_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071336","author":"MK Scheck","year":"2024","unstructured":"Scheck MK, Hofheinz RD, Lorenzen S. HER2-positive gastric cancer and antibody treatment: state of the art and future developments. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16071336.","journal-title":"Cancers (Basel)"},{"key":"1630_CR14","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1093\/annonc\/mdl475","volume":"18","author":"G Valabrega","year":"2007","unstructured":"Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007;18:977\u201384. https:\/\/doi.org\/10.1093\/annonc\/mdl475.","journal-title":"Ann Oncol"},{"key":"1630_CR15","doi-asserted-by":"publisher","first-page":"7479","DOI":"10.1158\/1078-0432.CCR-09-0636","volume":"15","author":"PR Pohlmann","year":"2009","unstructured":"Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res. 2009;15:7479\u201391. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0636.","journal-title":"Clin Cancer Res"},{"key":"1630_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12916-014-0132-3","volume":"12","author":"P Lavaud","year":"2014","unstructured":"Lavaud P, Andre F. Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials. BMC Med. 2014;12:132. https:\/\/doi.org\/10.1186\/s12916-014-0132-3.","journal-title":"BMC Med"},{"key":"1630_CR17","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.ccell.2016.05.005","volume":"29","author":"F Zanconato","year":"2016","unstructured":"Zanconato F, Cordenonsi M, Piccolo S. YAP\/TAZ at the Roots of Cancer. Cancer Cell. 2016;29:783\u2013803. https:\/\/doi.org\/10.1016\/j.ccell.2016.05.005.","journal-title":"Cancer Cell"},{"key":"1630_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s43018-022-00473-z","volume":"4","author":"S Piccolo","year":"2023","unstructured":"Piccolo S, Panciera T, Contessotto P, Cordenonsi M. YAP\/TAZ as master regulators in cancer: modulation, function and therapeutic approaches. Nat Cancer. 2023;4:9\u201326. https:\/\/doi.org\/10.1038\/s43018-022-00473-z.","journal-title":"Nat Cancer"},{"key":"1630_CR19","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.17582\/journal.pjz\/20220630020601","volume":"55","author":"W Wang","year":"2023","unstructured":"Wang W, Zhou MF, Liang YB, Zhang F, Wu Z, Mo SW, et al. YAP\/TAZ pathway promoted the trastuzumab resistance in HER2-positive breast cancer. Pak J Zool. 2023;55:2391\u20136. https:\/\/doi.org\/10.17582\/journal.pjz\/20220630020601.","journal-title":"Pak J Zool"},{"key":"1630_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051108","author":"P Gonzalez-Alonso","year":"2020","unstructured":"Gonzalez-Alonso P, Zazo S, Martin-Aparicio E, Luque M, Chamizo C, Sanz-Alvarez M, et al. The hippo pathway transducers YAP1\/TEAD induce acquired resistance to trastuzumab in HER2-positive breast cancer. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12051108.","journal-title":"Cancers (Basel)"},{"key":"1630_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.537265","author":"JQ Yuan","year":"2020","unstructured":"Yuan JQ, Ding NH, Xiao Z. The hippo transducer YAP\/TAZ as a biomarker of therapeutic response and prognosis in trastuzumab-based neoadjuvant therapy treated HER2-positive breast cancer patients. Front Pharmacol. 2020. https:\/\/doi.org\/10.3389\/fphar.2020.537265.","journal-title":"Front Pharmacol"},{"key":"1630_CR22","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ebiom.2019.04.061","volume":"43","author":"SS Islam","year":"2019","unstructured":"Islam SS, Uddin M, Noman AM, Akter H, Dity NJ, Basiruzzman M, et al. Antibody-drug conjugate T-DM1 treatment for HER2+ breast cancer induces ROR1 and confers resistance through activation of Hippo transcriptional coactivator YAP1. EBioMedicine. 2019;43:211\u201324. https:\/\/doi.org\/10.1016\/j.ebiom.2019.04.061.","journal-title":"EBioMedicine"},{"key":"1630_CR23","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1038\/s41388-018-0204-5","volume":"37","author":"J Shi","year":"2018","unstructured":"Shi J, Li F, Yao X, Mou T, Xu Z, Han Z, et al. The HER4\u2013YAP1 axis promotes trastuzumab resistance in HER2-positive gastric cancer by inducing epithelial and mesenchymal transition. Oncogene. 2018;37:3022\u201338. https:\/\/doi.org\/10.1038\/s41388-018-0204-5.","journal-title":"Oncogene"},{"key":"1630_CR24","doi-asserted-by":"publisher","first-page":"58007","DOI":"10.18632\/oncotarget.11157","volume":"7","author":"AR Nam","year":"2016","unstructured":"Nam AR, Kim JW, Cha Y, Ha H, Park JE, Bang JH, et al. Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget. 2016;7:58007\u201321. https:\/\/doi.org\/10.18632\/oncotarget.11157.","journal-title":"Oncotarget"},{"key":"1630_CR25","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1158\/1535-7163.MCT-16-0669","volume":"16","author":"MH Jin","year":"2017","unstructured":"Jin MH, Nam AR, Park JE, Bang JH, Bang YJ, Oh DY. Resistance mechanism against trastuzumab in HER2-positive cancer cells and its negation by Src inhibition. Mol Cancer Ther. 2017;16:1145\u201354. https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0669.","journal-title":"Mol Cancer Ther"},{"key":"1630_CR26","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1038\/s41388-022-02384-w","volume":"41","author":"KS Oh","year":"2022","unstructured":"Oh KS, Nam AR, Bang JH, Seo HR, Kim JM, Yoon J, et al. A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers. Oncogene. 2022;41:3939\u201352. https:\/\/doi.org\/10.1038\/s41388-022-02384-w.","journal-title":"Oncogene"},{"key":"1630_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2024.100625","volume":"5","author":"B Gyorffy","year":"2024","unstructured":"Gyorffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation (Camb). 2024;5: 100625. https:\/\/doi.org\/10.1016\/j.xinn.2024.100625.","journal-title":"Innovation (Camb)"},{"key":"1630_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17010138","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Huang T, Cheng AS, Yu J, Kang W, To KF. The TEAD family and its oncogenic role in promoting tumorigenesis. Int J Mol Sci. 2016. https:\/\/doi.org\/10.3390\/ijms17010138.","journal-title":"Int J Mol Sci"},{"key":"1630_CR29","doi-asserted-by":"publisher","first-page":"114576","DOI":"10.18632\/oncotarget.23051","volume":"8","author":"J Miao","year":"2017","unstructured":"Miao J, Hsu PC, Yang YL, Xu Z, Dai Y, Wang Y, et al. YAP regulates PD-L1 expression in human NSCLC cells. Oncotarget. 2017;8:114576\u201387. https:\/\/doi.org\/10.18632\/oncotarget.23051.","journal-title":"Oncotarget"},{"key":"1630_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1158\/2326-6066.CIR-17-0320","volume":"6","author":"MH Kim","year":"2018","unstructured":"Kim MH, Kim CG, Kim SK, Shin SJ, Choe EA, Park SH, et al. YAP-Induced PD-L1 expression drives immune evasion in BRAFi-resistant melanoma. Cancer Immunol Res. 2018;6:255\u201366. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0320.","journal-title":"Cancer Immunol Res"},{"key":"1630_CR31","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1111\/jcmm.13593","volume":"22","author":"PC Hsu","year":"2018","unstructured":"Hsu PC, Miao J, Wang YC, Zhang WQ, Yang YL, Wang CW, et al. Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma. J Cell Mol Med. 2018;22:3139\u201348. https:\/\/doi.org\/10.1111\/jcmm.13593.","journal-title":"J Cell Mol Med"},{"key":"1630_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.canlet.2018.05.009","volume":"430","author":"BKR Chaganty","year":"2018","unstructured":"Chaganty BKR, Qiu SB, Gest A, Lu Y, Ivan C, Calin GA, et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN\u03b3 secretion. Cancer Lett. 2018;430:47\u201356. https:\/\/doi.org\/10.1016\/j.canlet.2018.05.009.","journal-title":"Cancer Lett"},{"key":"1630_CR33","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s10120-021-01176-7","volume":"24","author":"MH Jin","year":"2021","unstructured":"Jin MH, Nam AR, Bang JH, Oh KS, Seo HR, Kim JM, et al. WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers. Gastric Cancer. 2021;24:1003\u201320. https:\/\/doi.org\/10.1007\/s10120-021-01176-7.","journal-title":"Gastric Cancer"},{"key":"1630_CR34","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1158\/1541-7786.MCR-19-0375","volume":"17","author":"Z Pan","year":"2019","unstructured":"Pan Z, Tian Y, Cao C, Niu G. The Emerging role of YAP\/TAZ in tumor immunity. Mol Cancer Res. 2019;17:1777\u201386. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-0375.","journal-title":"Mol Cancer Res"},{"issue":"1525\u201339","key":"1630_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.11.005","volume":"167","author":"T Moroishi","year":"2016","unstructured":"Moroishi T, Hayashi T, Pan WW, Fujita Y, Holt MV, Qin J, et al. The hippo pathway kinases LATS1\/2 suppress cancer immunity. Cell. 2016;167(1525\u201339): e17. https:\/\/doi.org\/10.1016\/j.cell.2016.11.005.","journal-title":"Cell"},{"key":"1630_CR36","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1038\/onc.2016.288","volume":"36","author":"S Murakami","year":"2017","unstructured":"Murakami S, Shahbazian D, Surana R, Zhang W, Chen H, Graham GT, et al. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene. 2017;36:1232\u201344. https:\/\/doi.org\/10.1038\/onc.2016.288.","journal-title":"Oncogene"},{"key":"1630_CR37","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-15-0224","volume":"6","author":"G Wang","year":"2016","unstructured":"Wang G, Lu X, Dey P, Deng P, Wu CC, Jiang S, et al. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov. 2016;6:80\u201395. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0224.","journal-title":"Cancer Discov"},{"key":"1630_CR38","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2015.07.013","volume":"162","author":"HW Park","year":"2015","unstructured":"Park HW, Kim YC, Yu B, Moroishi T, Mo JS, Plouffe SW, et al. Alternative Wnt signaling activates YAP\/TAZ. Cell. 2015;162:780\u201394. https:\/\/doi.org\/10.1016\/j.cell.2015.07.013.","journal-title":"Cell"},{"key":"1630_CR39","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1158\/0008-5472.Can-22-3003","volume":"83","author":"KS Wang","year":"2023","unstructured":"Wang KS, Ma F, Arai S, Wang Y, Varkaris A, Poluben L, et al. WNT5a signaling through ROR2 activates the hippo pathway to suppress YAP1 activity and tumor growth. Cancer Res. 2023;83:1016\u201330. https:\/\/doi.org\/10.1158\/0008-5472.Can-22-3003.","journal-title":"Cancer Res"},{"key":"1630_CR40","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2020105770","author":"O Guillermin","year":"2021","unstructured":"Guillermin O, Angelis N, Sidor CM, Ridgway R, Baulies A, Kucharska A, et al. Wnt and Src signals converge on YAP-TEAD to drive intestinal regeneration. Embo J. 2021. https:\/\/doi.org\/10.15252\/embj.2020105770.","journal-title":"Embo J"},{"key":"1630_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10051112","author":"JK Min","year":"2022","unstructured":"Min JK, Park HS, Lee YB, Kim JG, Kim JI, Park JB. Cross-talk between Wnt signaling and Src tyrosine kinase. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10051112.","journal-title":"Biomedicines"},{"key":"1630_CR42","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.cell.2014.06.013","volume":"158","author":"L Azzolin","year":"2014","unstructured":"Azzolin L, Panciera T, Soligo S, Enzo E, Bicciato S, Dupont S, et al. YAP\/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell. 2014;158:157\u201370. https:\/\/doi.org\/10.1016\/j.cell.2014.06.013.","journal-title":"Cell"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01630-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-025-01630-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-025-01630-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T14:14:20Z","timestamp":1756390460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-025-01630-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1630"],"URL":"https:\/\/doi.org\/10.1007\/s10120-025-01630-w","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"assertion":[{"value":"26 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Oh DY Consultant or advisory board member of AstraZeneca, Novartis, Genentech\/Roche, Merck Serono, Bayer, Taiho, ASLAN, Halozyme, Zymeworks, BMS\/Celgene, BeiGene, Basilea, Turning Point, and Yuhan. Research grant from AstraZeneca, Novartis, Array, Eli Lilly, Servier, BeiGene, MSD, and Handok.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of Seoul National University Hospital (IRB No. 2103-202-1208 for tumor tissue collection and IRB No. H-1811-106-987 for PBMC experiments). Written informed consent was obtained from all patients and healthy donors for research purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All participants were fully informed about the research study, its potential outcomes, and consented to the use of anonymized data for publication purposes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}